Drugs / Patent blue V
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07518485 | Apr 2026 → Mar 2027 expected | head and neck cancer, oral cavity cancer | Centre Hospitalier Universitaire Vaudois | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Patent blue V | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07518485 ↗ |
| Modality | Diagnostic / imaging agent | “The preReDSeL study evaluates the use of dyes (indocyanine green and Patent Blue V) for detecting these nodes.” NCT07518485 ↗ |
| Route | Other | “Patent Blue V dye is injected around the primary tumor.” NCT07518485 ↗ |